7月9日，伟思医疗今日收盘45.03元，下跌1.27%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到38.02倍，总市值43.13亿元。 来源：金融界 序号股票简称PE(TTM)PE(静)市净率总市值(元)13伟思医疗38.0242.292.5943.13亿行业平均 51.3648.894.49106.66亿行业中值37.2238.152.4951.36亿1九安医疗10.2510.370.81173.02亿2英科医疗 10.9511.800.97172.95亿3新华医疗14.3013.251.1791.67亿4奥美医疗15.3515.051.5855.47亿5振德医疗 15.3814.490.9855.82亿6山东药玻15.5415.591.79146.99亿7康德莱15.8115.821.3134.07亿8奥泰生物 16.4317.331.3352.40亿9维力医疗16.5717.221.9437.78亿10九强生物16.5815.422.0382.13亿11安杰思 17.3817.592.1051.60亿12三鑫医疗18.8118.813.0942.78亿 从行业市盈率排名来看，公司所处的 ...

7月9日，威高血净今日收盘37.69元，下跌1.10%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到33.88倍，总市值155.05亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均51.36倍，行业中值37.22倍，威高血净排 名第71位。 股东方面，截至2025年5月19日，威高血净股东户数59754户，较上次增加59736户，户均持股市值35.28 万元，户均持股数量2.76万股。 山东威高血液净化制品股份有限公司的主营业务为血液净化医用制品的研发、生产和销售。公司主要产 品包括血液透析器、血液透析管路、血液透析机以及腹膜透析液，分别围绕血液透析和腹膜透析领域， 辅以透析配套产品的销售，是国内产品线最为丰富的血液净化医用制品厂商之一。2022年公司在国内血 液透析器领域的市场份额占比为32.5%，位列全行业第一；在国内血液透析管路领域的市场份额占比为 32.8%，位列全行业第一；2022年公司获授权独家销售的威高泰尔茂品牌腹膜透析液在国内腹膜透析液 领域的市场份额占比为3.6%，位列全行业第五。 最新一期业绩显示，2025年一季报，公司实现营业收入8.96亿元，同比6.44% ...

Company Overview - Zhengchuan Co., Ltd. closed at 21.1 yuan, up 3.94%, with a rolling PE ratio of 74.00, marking a new low in 392 days, and a total market capitalization of 3.19 billion yuan [1] - The company specializes in the research, production, and sales of pharmaceutical packaging materials, including borosilicate glass vials, sodium-calcium glass vials, aluminum caps, and pre-filled syringe components [1] Financial Performance - For Q1 2025, the company reported revenue of 162 million yuan, a year-on-year decrease of 34.24%, and a net profit of 10.91 million yuan, down 48.15%, with a gross margin of 21.61% [1] Shareholder Information - As of March 31, 2025, the number of shareholders was 18,803, a decrease of 638 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 51.36, with a median of 37.22, placing Zhengchuan Co., Ltd. at 97th in the industry ranking [1][2] - The company’s static PE ratio is 59.91, and its price-to-book ratio is 2.64 [2]

会议为定向邀请制， 仅限企业CEO或核心高管参与 。会议具体地点及议程将在报名确认后，以专属通知形式 告知。 如您希望参会，请尽快与赵清（ 微信号 qingzhao2017 ）联系，提供您的公司名称、职务及联系方式，便于 完成初步确认。 思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 | 首届全球医美科技大会 为支持医疗器械企业更好地了解首都医疗创新政策，推动优质产品与临床场景深度对接，我们将于 7月17日 （周四）下午 在北京某医院举办一场限额闭门交流会，面向 北京以外地区的医疗器械企业高管 。 本次会议将聚焦以下几个方面： 即将召开： 2025年7月17日，第二届全球医疗科技大会 2025年9月3-5日，第三届全球手术机器人大会 北京市及属地政府相关负责人介绍支持政策与落地路径 药监局、医保局等主管部门讲解注册审评、市场准入与医保支付相关流程与重点关注事项 参观医院内若干创新技术临床应用场景，了解实际对接机会 企业间与政策方、医院的小范围深度对话 ...

2025年7月2日，NMPA公布了创新医疗器械特别审查申请审查结果公示（2025年第6号），宣布来自 深圳大 医伽玛刀科技有限公司 的 头部伽玛射线立体定向放射外科治疗系统 进入创新通道。 在技术层面，CybeRay 采用多束 钴-60 γ射线 ，通过几何聚焦实现高剂量精准照射，靶点定位精度达到 亚毫米 级（<0.5mm） 。系统搭载锥形束 CT（CBCT）或其他实时影像技术，能够在治疗过程中动态校正靶区位置， 显著减少因患者微小运动带来的治疗偏差。此外，其治疗规划软件集成了 AI 优化算法，可在短时间内制定个 体化剂量分布，提升治疗效率。 临床数据显示，CybeRay 的单次治疗时间通常在 30-60 分钟之间，治疗过程无创、无痛，患者无需开颅或住院 长时间观察，术后并发症发生率极低（<0.5%）。2023年，大连大学附属中山医院等国内多家医院已投入 CybeRay 使用，报道显示，患者五年生存率相比传统放疗提升 10-15%，术后恢复时间缩短约 30%。 在市场竞争层面，CybeRay 相较瑞典医科达 Leksell Gamma Knife，不仅在价格上更具优势（约低 30-40%）， 也凭借头体两用和实 ...

协办单位：启迪之星， 禾芫科技孵化器， 中关村科学城CGT产业孵化中心 五、大会议程 | 时间 主题和喜宾 | | | --- | --- | | 9:00-9:06 致辞环节 | | | 林航,海淀区 副区长(拟) | | | 刘慧,北京医药健康科技发展中心 主任(拟) | | | 王广志,清华大学 生物医学工程学院 执行 | | | 院长 (拟) | | | 9:06-9:15 | 全球科技创新系列奖项颁布 | | 9:15-9:35 | 医疗器械 BD: 现状与未来趋势 | | 9:35-9:55 | 《构建医院创新生态助力医工结合创新发 | | 展》 | | | 王昊 天坛医院科技处处长 | | | 9:55-10:15 | 题目待定 | | 逢宇 北京胸科医院 细菌免疫室主任和科研 | | | 处处长,结核病防治关键技术北京重点实验 | | | 室主任 | | | 10:15-10:35 《人工智能医疗器械产业发展探讨》 | | | 赵阳光,中国信息通信研究院云大所生物科 | | | 技部副主任 | | | 10:35-10:55 《可穿戴脑机接口与精神疾病诊疗》 | | | 左年明,中科院自动化所 ...

Core Viewpoint - Mindray Medical's stock closed at 214.48 yuan, down 1.31%, with a rolling PE ratio of 23.35 times and a total market capitalization of 260.04 billion yuan [1] Company Summary - Mindray Medical's main business includes research, manufacturing, marketing, and services of medical devices, with key products in life information and support, in vitro diagnostics, medical imaging, electrophysiology, and vascular intervention [1] - The latest quarterly report for Q1 2025 shows revenue of 8.237 billion yuan, a year-on-year decrease of 12.12%, and a net profit of 2.629 billion yuan, down 16.81%, with a gross profit margin of 62.53% [1] Industry Summary - The average PE ratio for the medical device industry is 51.36 times, with a median of 37.22 times, placing Mindray Medical at the 51st position in the industry ranking [1] - The recent data indicates that the main capital inflow for Mindray Medical on July 9 was 16.8342 million yuan, but over the past five days, there was a total outflow of 118.9931 million yuan [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Tongjing Life, which closed at 15.24 yuan with a PE ratio of 62.73, marking a new low in 75 days, and a total market capitalization of 2.477 billion yuan [1] - The average PE ratio for the medical device industry is 51.36, with a median of 37.22, placing Tongjing Life at the 92nd position in the industry ranking [1] - As of March 31, 2025, the number of shareholders for Tongjing Life is 17,040, a decrease of 590 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Tongjing Life focuses on the research, production, and sales of in vitro diagnostic products under its own brand, with major products including diagnostic reagents, instruments, and service income [1] - The company actively participates in various health-themed public welfare activities and has received multiple awards for its social responsibility efforts, including the "Social Public Welfare Award" from the China Cancer Foundation [1] - In the latest quarterly report for Q1 2025, Tongjing Life reported an operating revenue of 74.8931 million yuan, a year-on-year decrease of 19.53%, and a net profit of 471,700 yuan, a year-on-year increase of 110.51%, with a gross profit margin of 63.66% [1]

Company Overview - LeXin Medical focuses on health IoT and digital health services, offering products such as smart electronic blood pressure monitors, health scales, blood glucose monitoring devices, fat measuring instruments, ECG monitoring equipment, smart bands, and smartwatches [2] - The company is recognized as a national high-tech enterprise and has established several research and development centers, including the Guangdong Provincial Engineering Technology Research Center [2] - LeXin Medical has obtained various international certifications, including ISO13485:2016, ISO9001:2015, ISO14001:2015, FDA registration, CE certification, and others, indicating its commitment to quality and international standards [2] Financial Performance - In the first quarter of 2025, LeXin Medical reported revenue of 273 million yuan, representing a year-on-year increase of 9.90%, and a net profit of 22.94 million yuan, up 67.88% year-on-year, with a gross profit margin of 37.38% [2] - As of July 9, 2023, the company's stock closed at 15.85 yuan, with a rolling PE ratio of 48.79, marking a new low in 65 days, and a total market capitalization of 3.447 billion yuan [1] Industry Comparison - The average PE ratio for the medical device industry is 51.36, with a median of 37.22, placing LeXin Medical at the 87th position within the industry [1][3] - The company's current PE ratio is lower than the industry average, indicating potential valuation opportunities [1][3]

Company Overview - The main business of the company is the research, production, sales, and related services of in vitro diagnostic products, including a wide range of test reagents for liver function, kidney function, glucose metabolism, lipid metabolism, infectious diseases, and more [2]. Financial Performance - In the first quarter of 2025, the company reported revenue of 510 million yuan, a year-on-year decrease of 17.22%, and a net profit of 23.98 million yuan, down 80.09% year-on-year, with a gross profit margin of 56.76% [2]. Market Position - As of July 9, the company's stock closed at 12.24 yuan, up 1.92%, with a rolling price-to-earnings (PE) ratio of 247.07, marking a new low in 65 days. The total market capitalization is 7.497 billion yuan [1]. - The average PE ratio in the medical device industry is 51.36, with a median of 37.22, placing the company at the 119th position in the industry ranking [1][3]. Shareholder Information - As of March 31, 2025, the number of shareholders is 35,022, a decrease of 1,242 from the previous count, with an average holding value of 352,800 yuan and an average holding of 27,600 shares per shareholder [1].